Amalgamation of Takeda Canada Inc. and Shire Pharma Canada ULC Solidifies Company’s Leadership Position in Canadian Biopharmaceutical Industry
Updated COVID-19 Healthcare Professional Letter
Self-injectable formulation of ENTYVIO® (vedolizumab) approved in Canada for the maintenance treatment of moderately to severely active ulcerative colitis
COVID-19 HCP Letter
Takeda Canada Announces Significant Investment in First Collaborative Canadian Lung Cancer Research Project with Princess Margaret Cancer Centre
